image: This graphic illustrates that the B cell response containing antibodies that target dengue serotype 2 appear two weeks after a dengue serotype 2 infection in humans and are still present 6 months after infection. Such B cells are important players in long-term protection from future dengue 2 infections. view more
Credit: Sean Diehl, Ph.D., UVM Larner College of Medicine
About 40 percent of the global population is at risk for contracting dengue - the most important mosquito-borne viral infection and a close "cousin" of the Zika virus - and yet, no effective treatment or safe licensed vaccine exists. But a new study, reported recently in the Lancet's open-access journal EBioMedicine, has uncovered details about the human immune response to infection with dengue that could provide much-needed help to the evaluation of dengue vaccine formulations and assist with advancing safe and effective candidate vaccines.
Like Zika, yellow fever and West Nile viruses, dengue belongs to a group of mosquito-borne viruses that circulate in many tropical countries. However, without effective treatment and a safe licensed vaccine, dengue infection can lead to debilitating illnesses, including severe pain and hemorrhagic fever. One of the challenges of dengue infection is that it can be caused by one of four versions - or serotypes - of the virus, which are numbered dengue 1 to 4. Infection by one serotype typically results in long-term protection specific to that serotype. However, a later exposure to a different serotype can result in more severe disease. Experts believe this phenomenon occurs due to a part of the immune response, the antibodies, which may recognize and promote the second infection rather than defeat it.
"Trying to tease out the protective immune response in naturally infected patients is a challenge, since people living in high-risk areas likely have been exposed to multiple serotypes of the virus, which confound the observation," said senior study author Sean Diehl, Ph.D., an assistant professor of microbiology and molecular genetics at the University of Vermont's (UVM) Vaccine Testing Center and Center for Translational Global Infectious Disease Research. "In our model, we controlled the infection for safety reasons and the participants were monitored for six months in order to understand the biological changes that occur following the infection."
Over a six-month period, Diehl and his colleagues tracked the immune response and measured its different aspects, from the levels of certain immune blood cells to the levels of antibodies they produce and how these antibodies can recognize different dengue serotypes. In this study, co-led by Huy Tu, a fifth-year Ph.D. candidate in UVM's Cellular and Molecular Biomedical Sciences program, the group defined the evolution of the antibody response in dengue infection in a controlled human model where subjects were treated with a weakened version of the virus.
The research showed that the study participants developed an antibody response against the virus as early as two weeks after the infection. This immune response was highly focused against the infecting serotype, neutralized the virus, and persisted for months afterwards. With a comprehensive approach, the study dissected the antibody response at the single-cell level resolution, mapped the interaction between human antibodies to structural components on the virus's surface, and connected the functional features of the response during acute infection to time points past recovery.
###
In addition to Diehl and Tu, UVM co-investigators on the study included Beth Kirkpatrick, M.D., chair and professor of microbiology and molecular genetics and medicine, and Kristen Pierce, M.D., associate professor of medicine. This work is the result of a longstanding collaboration between the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, the Johns Hopkins University Bloomberg School of Public Health, the University of North Carolina at Chapel Hill, and the Vaccine Testing Center at UVM. This research received support from the Bill and Melinda Gates Foundation, National Institute of Allergy and Infectious Disease and the National Institutes of General Medical Sciences.
Journal
EBioMedicine